Drug Development

Articles

The use of therapeutic vaccines presents a new way to manage diseases, such as cancer and sexually transmitted diseases.

Therapeutic Vaccines Target Cancer and Other Viral-Induced Diseases

Adrian Wildfire is project director, Infectious Diseases &Viral Challenge Unit, SGS Life SciencesâClinical Research.

Challenge trials may increase in coming years as new and improved challenge agents better emulate “natural” disease states. 

Using Human Challenge Trials to Develop Flu Vaccines

Agnes Shanley is senior editor of Pharmaceutical Technology.

Despite the challenges and high cost of development, vaccine innovation is at an all-time high, as new approaches aim to improve global access.

Making Vaccines Accessible

Amber Lowry is an associate editor at UBM plc.

This article explores some of the challenges, services, and technologies that go into ensuring that vaccines are properly temperature controlled and maintain product integrity for delivery to patients.

Cold Chain: Delivering Vaccines to Patients

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

The use of approved platform technologies can reduce the time and cost required to generate new vaccines.

Accelerating Vaccine Development and Manufacturing

ADC Bio experts warn of impending problems in the ADC pipeline with millions wasted in development costs.

ADC Targets Fail Because of Aggregation Problems

Company completes first successful run of what is believed to be the largest synthesis-scale done for oligonucleotide APIs.

Nitto Avecia Completes Large-Scale Synthesis of Oligonucleotide

The companies have established a joint laboratory to develop full continuous processing to manufacture high yields of monoclonal antibodies at reduced costs.

WuXi and Pall Establish Continuous MAb Manufacture

The EMA’s Committee for Medicinal Products for Human Use has recommended marketing authorization approval for AstraZeneca’s benralizumab, a monoclonal antibody for treating severe asthma.

AstraZeneca Gets Positive EMA Opinion on Respiratory Biologic

The company expects to commercially launch the new vaccine in the US in the first quarter of 2018.

Formulation and Drug Delivery